BIBLIOGRAFIA

BIBLIOGRAFIA

Bibliografia
193
A
Adams JM, Harris AW, Strasser A, Ogilvy S and Cory S (1999) Transgenic models of lymphoid
neoplasia and development of a pan-hematopoietic vector. Oncogene 18:5268-77.
Aguayo C, Casado J, Gonzalez M, Pearson JD, Martin RS, Casanello P, Pastor-Anglada M and
Sobrevia L (2005) Equilibrative nucleoside transporter 2 is expressed in human umbilical
vein endothelium, but is not involved in the inhibition of adenosine transport induced by
hyperglycaemia. Placenta 26:641-53.
Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G and Liliemark J
(1998) Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-
triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer
Res 4:653-8.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu
X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R,
Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R,
Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM (2000) Distinct types
of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-11.
Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C and Giles FJ (2002) Troxacitabine
activity in extramedullary myeloid leukemia. Hematology 7:179-85.
Anderson CM, Xiong W, Young JD, Cass CE and Parkinson FE (1996) Demonstration of the
existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat
brain. Brain Res Mol Brain Res 42:358-61.
Aran JM and Plagemann PG (1992) Nucleoside transport-deficient mutants of PK-15 pig kidney cell
line. Biochim Biophys Acta 1110:51-8.
Arner ES and Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155-
86.
Arner ES, Flygar M, Bohman C, Wallstrom B and Eriksson S (1988) Deoxycytidine kinase is
constitutively expressed in human lymphocytes: consequences for compartmentation effects,
unscheduled DNA synthesis, and viral replication in resting cells. Exp Cell Res 178:335-42.
Arner ES, Spasokoukotskaja T, Juliusson G, Liliemark J and Eriksson S (1994) Phosphorylation of 2-
chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic
patients. Br J Haematol 87:715-8.
Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
Nat Rev Cancer 2:420-30.
Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman
GH and Sato JK (1998) Pharmacokinetic and pharmacodynamic studies of fludarabine and
cytosine arabinoside administered as loading boluses followed by continuous infusions after
a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer
Group. Clin Cancer Res 4:45-52.
Aymerich I, Duflot S, Fernandez-Veledo S, Guillen-Gomez E, Huber-Ruano I, Casado FJ and Pastor-
Anglada M (2005) The concentrative nucleoside transporter family (SLC28): new roles
beyond salvage? Biochem Soc Trans 33:216-9.
Aymerich I, Pastor-Anglada M and Casado FJ (2004) Long term endocrine regulation of nucleoside
transporters in rat intestinal epithelial cells. J Gen Physiol 124:505-12.
B
Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ and Peters GJ (2000)
Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-
fluorouracil and antifolates. Oncol Res 12:231-9.
Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE,
Carlson EJ, Burchard EG and Giacomini KM (2005) Functional analysis of genetic variants
in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics
J 5:157-65.
Bai L, Yamaguchi M, Tatsumi M, Kon K and Brautigam M (1998) Mechanisms responsible for
resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-
arabinofuranosyl-2-fluoroadenine. J Cancer Res Clin Oncol 124:367-73.

Paper dels ENTs en la sensibilitat a fàrmacs antineoplàsics
194
Baldwin SA, Beal PR, Yao SY, King AE, Cass CE and Young JD (2004) The equilibrative nucleoside
transporter family, SLC29. Pflugers Arch 447:735-43.
Baldwin SA, Mackey JR, Cass CE and Young JD (1999) Nucleoside transporters: molecular biology
and implications for therapeutic development. Mol Med Today 5:216-24.
Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE and Young JD
(2005) Functional characterization of novel human and mouse equilibrative nucleoside
transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem
280:15880-7.
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y,
Shiloh Y and Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA
damage. Science 281:1674-7.
Barak Y, Juven T, Haffner R and Oren M (1993) mdm2 expression is induced by wild type p53
activity. Embo J 12:461-8.
Belt JA, Harper EH, Byl JA and Noel LA (1992) Sodium-dependent nucleoside transport in human
myeloid leukemic cell lines and freshly isolated myeloblast. Proc Am Assoc Cancer Res 22,
20.
Belt JA, Marina NM, Phelps DA and Crawford CR (1993) Nucleoside transport in normal and
neoplastic cells. Adv Enzyme Regul 33:235-52.
Bertoni F, Zucca E and Cotter FE (2004) Molecular basis of mantle cell lymphoma. Br J Haematol
124:130-40.
Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-6.
Bhalla K, Nayak R and Grant S (1984) Isolation and characterization of a deoxycytidine kinase-
deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-
arabinofuranosylcytosine. Cancer Res 44:5029-37.
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P,
Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit
M, Belabbes S and Gremy F (1981) A new prognostic classification of chronic lymphocytic
leukemia derived from a multivariate survival analysis. Cancer 48:198-206.
Biswal SS, Datta K, Acquaah-Mensah GK and Kehrer JP (2000) Changes in ceramide and
sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells.
Toxicology 154:45-53.
Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev
Biochem 71:537-92.
Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales
M, Esteve J, Altes A, Besalduch J, Ribera JM and Montserrat E (2002) Fludarabine,
cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic
lymphocytic leukaemia. Br J Haematol 119:976-84.
Boyum A (1964) Separation of White Blood Cells. Nature 204:793-4.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of
protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-54.
Brockman RW, Schabel FM, Jr. and Montgomery JA (1977) Biologic activity of 9-beta-D-
arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-
arabinofuranosyladenine. Biochem Pharmacol 26:2193-6.
Brown NC and Reichard P (1969) Role of effector binding in allosteric control of ribonucleoside
diphosphate reductase. J Mol Biol 46:39-55.
Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G,
Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Jr. and Appella E (2002)
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat
Genet 31:210-5.
Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from sodium dodecyl
sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with
antibody and radioiodinated protein A. Anal Biochem 112:195-203.
Byrd JC, Rai KR, Sausville EA and Grever MR (1998) Old and new therapies in chronic lymphocytic
leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 25:65-74.

Bibliografia
195
C
Campo E (2003) Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I:
mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. Hum Pathol 34:330-5.
Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP and
Pastor-Anglada M (2004) Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase
with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 9:993-1002.
Cao TM and Coutre SE (2003) Management of advanced chronic lymphocytic leukemia. Curr
Hematol Rep 2:65-72.
Capello D and Gaidano G (2000) Molecular pathophysiology of indolent lymphoma. Haematologica
85:195-201.
Caras IW and Martin DW, Jr. (1988) Molecular cloning of the cDNA for a mutant mouse
ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian
cells. Mol Cell Biol 8:2698-704.
Cass CE, Dahlig E, Lau EY, Lynch TP and Paterson AR (1979) Fluctuations in nucleoside uptake
and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the
replication cycle of HeLa cells. Cancer Res 39:1245-52.
Chan JK (2001) The new World Health Organization classification of lymphomas: the past, the
present and the future. Hematol Oncol 19:129-50.
Chan TC (1989) Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor
cells by inhibiting drug efflux. Cancer Res 49:2656-60.
Chandrasena G, Giltay R, Patil SD, Bakken A and Unadkat JD (1997) Functional expression of
human intestinal Na+-dependent and Na+-independent nucleoside transporters in Xenopus
laevis oocytes. Biochem Pharmacol 53:1909-18.
Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD and Unadkat JD (2004) Molecular requirements of
the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 65:558-70.
Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh
DM, Gill K, Uzzell M, Prior Y and Catovsky D (2003) Gemcitabine, cisplatin and
methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor
prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Br J Haematol 120:970-7.
Che M, Ortiz DF and Arias IM (1995) Primary structure and functional expression of a cDNA
encoding the bile canalicular, purine-specific Na(+)-nucleoside cotransporter. J Biol Chem
270:13596-9.
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A and Kipps TJ (2002) Expression of ZAP-
70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Blood 100:4609-14.
Chen SF, Stoeckler JD and Parks RE, Jr. (1984) Transport of deoxycoformycin in human
erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays.
Biochem Pharmacol 33:4069-79.
Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the
concentration of inhibitor which causes 50 per cent inhibition (IC50) o fan enzymatic reaction.
Biochem Pharmacol 22:3099-108.
Chiorazzi N, Rai KR and Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-15.
Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A and
Messing RO (2004) The type 1 equilibrative nucleoside transporter regulates ethanol
intoxication and preference. Nat Neurosci 7:855-61.
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-9.
Chow L, Lai R, Dabbagh L, Belch A, Young JD, Cass CE and Mackey JR (2005) Analysis of human
equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by
immunohistochemistry. Mod Pathol 18:558-64.
Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM and
Aubert C (2002) Transmission of apoptosis in human colorectal tumor cells exposed to
capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 1:923-7.
Coe I, Zhang Y, McKenzie T and Naydenova Z (2002) PKC regulation of the human equilibrative
nucleoside transporter, hENT1. FEBS Lett 517:201-5.